New hope for rare cancers: immunotherapy drug dostarlimab takes on chemo in phase 2 trial
NCT ID NCT06333314
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing whether the immunotherapy drug dostarlimab can work better than standard chemotherapy as a first treatment for people with rare, advanced cancers that have a specific genetic flaw called dMMR/MSI. The study includes 120 adults with cancers like pancreatic, stomach, or small bowel cancer that cannot be surgically removed. Patients are randomly assigned to receive either dostarlimab or chemotherapy, and those on chemotherapy may switch to dostarlimab if their disease gets worse.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Dostarlimab (an immunotherapy drug that helps the immune system attack cancer cells)
- What this could lead to
- If it works, this could provide a new first-line treatment option for people with rare cancers that have specific genetic features, potentially delaying disease progression.
- What could go wrong
- This is a phase 2 trial with only 120 participants, so results are preliminary. The drug may not work better than chemotherapy, and immunotherapy can cause immune-related side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADRENOCORTICAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHU - Henri Mondor
NOT_YET_RECRUITINGCréteil, France
-
CHU Jean Minjoz
NOT_YET_RECRUITINGBesançon, France
-
CHU Morvan
NOT_YET_RECRUITINGBrest, France
-
CHU de Bordeaux - Hôpital Haut -Lèvêque
NOT_YET_RECRUITINGPessac, France
-
CHU de Poitiers
NOT_YET_RECRUITINGPoitiers, France
-
CHU de Rouen
NOT_YET_RECRUITINGRouen, France
-
CHU de Toulouse Hôpital Rangueil
NOT_YET_RECRUITINGToulouse, France
-
Centre Eugène Marquis
NOT_YET_RECRUITINGRennes, France
-
Centre François Baclesse
NOT_YET_RECRUITINGCaen, France
-
Centre Georges François Leclerc
NOT_YET_RECRUITINGDijon, France
-
Centre Jean Perrin
NOT_YET_RECRUITINGClermont-Ferrand, France
-
Centre Léon Bérard
RECRUITINGLyon, France
-
Gustave Roussy Grand Paris
NOT_YET_RECRUITINGVillejuif, France
-
Hôpital Saint-Antoine
NOT_YET_RECRUITINGParis, Île-de-France Region, France
-
Hôpital la Timone
NOT_YET_RECRUITINGMarseille, France
-
Institut Jean Godinot
NOT_YET_RECRUITINGReims, France
-
Institut Mutualiste Montsouris
NOT_YET_RECRUITINGParis, France
-
Institut Paoli Calmettes
NOT_YET_RECRUITINGMarseille, France
-
Institut de Cancérologie de Lorraine
NOT_YET_RECRUITINGNancy, France
-
Institut de Cancérologie de l'Ouest
NOT_YET_RECRUITINGAngers, France
-
Institut de Cancérologie de l'Ouest
NOT_YET_RECRUITINGSaint-Herblain, France
-
Institut du Cancer Avignon-Provence
NOT_YET_RECRUITINGAvignon, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can AI-Guided home training boost recovery from gastric cancer surgery?
- Can a radioactive antibody light up hidden tumors?
- Can a new drug combo shrink Hard-to-Treat tumors?
- A simple blood test may reveal hidden infertility risk in young cancer survivors
- Can a pill rouse the immune system against pancreatic cancer?
- Can immunotherapy outperform chemo after stomach cancer surgery?